The efficacy of trastuzumab injection (subcutaneous injection) (Herceptin Hylecta)

Trastuzumab injection (subcutaneous ) (Herceptin Hylecta) is a drug used to treat HER2-positive breast cancer. HER2-positive breast cancer is a specific type of breast cancer in which the HER2 protein is overexpressed on the surface of the cells. Trastuzumab injection is a targeted therapy drug that prevents the growth and division of breast cancer cells by inhibiting the activity of the HER2 protein. It can be administered by subcutaneous injection.

Approval of trastuzumab injection (subcutaneous ) was based on two randomized trials in which participants were randomly assigned to receive 8 cycles of trastuzumab injection (subcutaneous ) or intravenous trastuzumab plus chemotherapy, followed by surgery and continuation of treatment for 10 cycles. Comparability between trastuzumab injection (subcutaneous) and intravenous trastuzumab was demonstrated based on co-primary endpoints of pathological complete response and pharmacokinetics. Pathologic complete responses (pCR) were observed in 118 participants (45.4%) in the subcutaneous trastuzumab injection group and 107 participants (40.7%) in the intravenous trastuzumab group.

It is understood that the original drug of trastuzumab injection (subcutaneous injection) has been launched in China, but the specific price and other relevant information are not yet clear. Since the drug has been on the market for a short time, it has not been included in the scope of medical insurance. At present, there are no generic drugs of Trastuzumab injection (subcutaneous injection) produced and marketed. For more information and specific prices of Trastuzumab injection (subcutaneous injection), please consult a medical consultant.